Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

Abstract

With respect to HbA(1c), BIAsp 30 fulfilled the statistical criteria for non-inferiority and superiority to insulin glargine and, according to pre-defined criteria, the improvements in HbA(1c) are considered clinically equivalent. Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30. There were no differences in treatment satisfaction between the two groups.

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A 1 chieve study

“…As a result, PPPG control with BIAsp 30 has been proven to be superior to basal-insulin therapy in randomized controlled trials. [678] Furthermore, these studies also suggest that HbA 1c control with BIAsp 30 is comparable or superior to basal levels of insulin. This efficiency in glycemic control was associated with an overall low risk of hypoglycemia, except for nocturnal events.…”

Management of diabetes mellitus type-2 in the geriatric population: Current perspectives

“…Better adherence and compliance to the therapy with premixed insulin group was the main reason behind this. [45]…”

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

“…Some authorities endorse both basal and premix approaches, and others place more emphasis on basal insulin; mealtime insulin alone is used on occasion, or in a comprehensive mealtime + basal regimen even from the time of starting insulin [4]. Randomized clinical trials have provided evidence on the relative efficacy of insulin regimens [5,6], but these trials were conducted in people and clinical environments that may not be representative of those in routine clinical practice. Little is known of the impact of starting insulin for outcomes of importance to people with diabetes, such as change in insulin regimen, insulin dose, hypoglycaemia and weight change, with data available only for single countries ( [7][8][9]), or in less or recently developed nations [4], or particular insulins [10,11], often with follow-up of one year or less [4,7,8].…”